Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 study

HIV Clinical Trials

Volumn 3, Issue 3, 2002, Pages 177-185

  French, Martyn ^a   Amin, Janaki ^a   Roth, Norman ^a   Carr, Andrew ^a   Law, Matthew ^a   Emery, Sean ^a   Drummond, Fraser ^a   Cooper, David ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Combination antiretroviral therapy; HIV; Nevirapine

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANXIETY; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL ASSESSMENT; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; VIRUS LOAD;

EID: 0036306243     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/9N21-1HG1-7N1Q-JKW1     Document Type: Article

References (11)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group
3. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: Preliminary safety and efficacy results. VIRGO Study Team
4. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection
5. Variations in population health status: Results from a United Kingdom national questionnaire survey
6. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: Selection of thymidine analog regimen therapy (START I)
7. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)
8. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: The OzCombo 1 study
9. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
10. Analyses of four key clinical trials to assess the risk of hepatotoxicity with nevirapine: Correlation with CD4+ levels, hepatitis B & C seropositivity, and baseline liver function tests
11. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy